Global Blood Therapeutics, Inc.
GBT · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $72 | $55 | $56 | $52 |
| % Growth | 29.7% | -1.7% | 7.8% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $70 | $54 | $55 | $51 |
| % Margin | 98% | 98.1% | 97.9% | 98.4% |
| R&D Expenses | $65 | $53 | $59 | $51 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $81 | $75 | $79 | $68 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $146 | $127 | $138 | $119 |
| Operating Income | -$74 | -$73 | -$83 | -$67 |
| % Margin | -103.3% | -132.4% | -148.3% | -129.3% |
| Other Income/Exp. Net | -$7 | -$8 | -$4 | -$4 |
| Pre-Tax Income | -$82 | -$81 | -$87 | -$71 |
| Tax Expense | $0 | $0 | $4 | $0 |
| Net Income | -$82 | -$81 | -$91 | -$71 |
| % Margin | -115.3% | -147.6% | -163.1% | -136.4% |
| EPS | -1.26 | -1.26 | -1.42 | -1.13 |
| % Growth | 0% | 11.3% | -25.7% | – |
| EPS Diluted | -1.26 | -1.26 | -1.42 | -1.13 |
| Weighted Avg Shares Out | 66 | 65 | 64 | 63 |
| Weighted Avg Shares Out Dil | 66 | 65 | 64 | 63 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $0 | $0 |
| Interest Expense | $8 | $8 | $4 | $4 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | -$72 | -$71 | -$80 | -$65 |
| % Margin | -100% | -128.3% | -143.5% | -125% |